Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oncolytics Biotech, Inc. (NASDAQ:ONCY) has been given an average broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company.
Brokerages have set a 12-month consensus price objective of $8.74 for the company and are predicting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Oncolytics Biotech an industry rank of 57 out of 255 based on the ratings given to related companies.
Tickerreport.com
Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the business's stock in a transaction on Monday, December 30th. The shares were acquired at an average cost of $1.47 per share, with a total value of $147,000.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company's stock, valued at $4,511,357.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the business's stock in a transaction on Friday, December 27th. The shares were acquired at an average cost of $1.49 per share, with a total value of $149,000.00.
(NASDAQ:ONCY) had its price target raised by Roth Capital (* ) (analyst J. Isaacson) from $6.80 to $9.00. They now have a "buy" rating on the stock. 163.9% upside from the current price of $3.41.
That would be fantastic!
Happy New Year to you!
TY! Happy I picked up shares!
Hi timetraveler, GLTY. ONCY has been on my biotech watch list for awhile. 2020 should be interesting!
Hi Mcsharkey, PM looking interesting today. Wondering if it will dip at any point after opening bell or just full speed ahead. Obviously lots of interest.
GLTY
Watching Monday morning to see how this holds. Could continue on this upward trajectory. If there is a slight pullback, I may grab a few shares.
Planning on getting a starter position tomorrow. Mayo Clinic brain cancer trial, glioblastoma clinical trial, pipeline looks interesting, IMO.
Added this one to my watch list. Looking promising with the Cantor Fitzgerald overweight rating and PT of $18.
Crudeoil24- I spend a fair amount of time researching my next moves. I try to stay out of the fray on some of these boards. Lol
GLTY!
Crudeoil24- I still have a position in CRTX. I came across SYRS recently though and couldn’t resist buying in!
Picking up a few more shares today. With more good news, this is a no-brainer, IMO.
I bought in when they announced the partnership with GBT. Nice upward movement the last two days.
SRNE has a consensus rating of “Buy” and an average price target of $16.19.
SRNE stock opened at $4.07 on Friday (12/13/19). The company has a quick ratio of 0.56, a current ratio of 0.60 and a debt-to-equity ratio of 43.15. The stock’s 50 day simple moving average is $2.28 and its 200 day simple moving average is $2.41. Sorrento Therapeutics Inc has a fifty-two week low of $1.39 and a fifty-two week high of $6.50.
https://trentdailytimes.com/2019/12/14/sorrento-therapeutics-inc-nasdaqsrne-stake-boosted-by-tower-research-capital-llc-trc-updated.html
Long here. GLTA
JMP Securities rated SRNE as Market Outperform with a price target of $21. Market cap is $215.6 million.
Equillium Shares Up 16% After Getting FDA Fast-Track Designation
12/10/19, 1:37 PM
Equillium Inc. (EQ) shares rose 16% to $4.68 after the company said the U.S. Food and Drug Administration has granted fast-track designation for itolizumab for the treatment of lupus nephritis.
Equillium said it initiated the Equalise Phase 1b study of itolizumab in patients with lupus and lupus nephritis in September.
The biotechnology company said the trial will be assessing the opportunity to take a personalized medicine approach to identify patients where the CD6-ALCAM pathway may be a dominant driver of the disease. There are currently no FDA- approved therapies for lupus nephritis, Equillium said.
Moving up pre market. Currently $11.22 at 8:30 am. Closed at $10.71 yesterday.
GLTA
Nice pre market action this morning!
GLTA
I would be ok with a BO before Christmas. I have 2 kids in college with tuition bills due soon!
Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer’s Disease
12/7/19, 1:00 PM
– In a Phase 1b trial, COR388 reduced levels of fragmented ApoE protein in cerebrospinal fluid of subjects with Alzheimer’s –
–The drug’s target, the gingipains from P. gingivalis bacteria, preferentially attack the protein encoded by an APOE genetic variant associated with increased risk for Alzheimer’s –
SAN DIEGO & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentation of new data supporting the on-target activity of COR388, its lead investigational medicine, and linking the “gingipain hypothesis” for Alzheimer’s disease (AD) to the significance of the APOE gene as a major risk factor for the disease. Michael Detke, M.D., Ph.D., the company’s chief medical officer, detailed the results in an oral presentation (abstract #OC28) at the 2019 Clinical Trials in Alzheimer’s Disease (CTAD) meeting, which is being held December 4-7, 2019 in San Diego.
Today’s CTAD presentation is centered on two findings related to the growing interest in ApoE fragmentation as a potential pathogenic mechanism for sporadic Alzheimer’s disease:
Gingipains from P. gingivalis cleave ApoE proteins and have a preference for cleaving ApoE4; and COR388, a gingipain inhibitor, prevents this. In in vitro experiments, cells infected with P. gingivalis exhibited gingipain-dependent ApoE cleavage activity that generated ApoE fragments similar to what was seen in the brains and cerebrospinal fluid (CSF) of patients with Alzheimer’s disease. In contrast, uninfected cells had no significant ApoE protein-cleaving activity. Furthermore, P. gingivalis gingipains cleaved ApoE4 more readily than ApoE3. Finally, in the infected cells, COR388 alone was sufficient to block ApoE fragmentation.
In a Phase 1b trial, COR388 reduced ApoE fragments in CSF. Cortexyme’s Phase 1 clinical development program for COR388 included cohorts of healthy volunteers and subjects with Alzheimer’s disease. In addition to assessing safety and initial clinical activity, investigators also assessed the level of ApoE fragmentation in the CSF of nine subjects with Alzheimer’s disease. Six subjects received 50mg of COR388 twice daily while three subjects received placebo. After 28 days, a statistically significant decrease in ApoE fragments (both ApoE4 and ApoE3) was observed in subjects treated with COR388 versus those treated with placebo.
“The APOE gene is known to significantly impact Alzheimer’s risk, with the APOE2 variant playing a protective role and APOE4 associated with a much higher risk for developing the disease,” said Dr. Detke. “The data presented today further illuminate the potential relationship between APOE-driven genetic risk and the presence of gingipains from P. gingivalis in the brain, which we have found in 90-100% of Alzheimer’s patients, depending on the method of measurement.”
“Recent research has shown that the APOE gene may play a larger role than previously believed in Alzheimer’s disease development, suggesting that a solid understanding of APOE is important to a comprehensive hypothesis of Alzheimer’s causation,” said Casey Lynch, Cortexyme’s chief executive officer, co-founder, and chair, and a co-author of today’s presentation. “We believe the data presented today provide insight into why APOE4 increases the risk for Alzheimer’s disease: the ApoE4 protein, which is important for synaptic maintenance and control of neuroinflammation, has a higher propensity to be fragmented by gingipains, compared to other forms of ApoE. Importantly, our human studies have shown the ability of COR388 to protect ApoE proteins from gingipain fragmentation in the brains of study subjects.”
A growing body of evidence points to P. gingivalis as playing a key role in the development of Alzheimer’s disease given its identification in the brains of AD patients and its ability to cause neurodegeneration, inflammation, beta-amyloid and tau buildup, and other pathology associated with the disease in animal models. An asacchrolytic bacterium, P. gingivalis has been shown to infiltrate the brain and release toxic proteases called gingipains that cleave ApoE, tau, and other proteins associated with neuronal function. Cortexyme is developing COR388, an investigational small-molecule gingipain inhibitor that is currently in a large, international Phase 2/3 clinical trial (the GAIN Trial). This trial is evaluating the efficacy, safety, and tolerability of COR388 in patients with mild to moderate AD, with top-line results expected in the fourth quarter of 2021.
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s disease and other degenerative diseases. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. The company’s lead investigational medicine, COR388, is the subject of the GAIN Trial, an ongoing Phase 2/3 clinical study in patients with mild to moderate Alzheimer’s. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter
Here’s hoping for info on Monday. Would make a great Christmas bonus for a lot of people! ??
Watch for Scilex IPO news as well. It would be another catalyst for SRNE.
Holding for now.
GLTA
Waiting for the ASH conference this weekend before making a decision. A BO is still a possibility, and car-t and RTX are potential catalysts to propel this upwards.
I bought in yesterday at $3.04. Hoping that the slow & steady climb continues.
Looking forward to the ASH conference Dec. 7-10.
GLTA
Agreed! GLTY
Nice movement today- high of $3.41 now.
Doing well pre-market. Should be an interesting Black Friday! GLTY
Would love to see this continue the upward trend to the analyst ratings of $10-$12 on Friday/next week. It would make for an awesome holiday season!
Hepion Pharmaceuticals up 41%
11/27/19, 1:03 PM
Hepion Pharmaceuticals Inc. (HEPA) shares recently traded up 41% to $6.52.
The company didn't appear to issue any press releases or filings on Wednesday.
Last Wednesday, Hepion shares closed at $2.45, and surged after the company said its CRV431 drug prevented the development of liver cirrhosis in a study of liver disease with rats.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
11-27-19 1303ET
Copyright (c) 2019 Dow Jones & Company, Inc.
Piper Jaffray Initiates Coverage on Opko Health With Overweight Rating, $2.50 Price Target
11/25/19, 8:42 AM
08:42 AM EST, 11/25/2019 (MT Newswires) -- Opko Health's (OPK) average rating among analysts is a buy, with an average price target of $3.
Price: 1.6500, Change: +0.04, Percent Change: +2.48
Looks like this has legs today! About time.
Hepion Pharmaceuticals Price Target Announced at $12.00/Share by Brookline Capital
11/22/19, 10:03 AM
Ratings actions from Benzinga: https://www.benzinga.com/stock/HEPA/ratings
(END) Dow Jones Newswires
11-22-19 1003ET
HEPA trading above $4 in pre-market. Great news out!
MW Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatment
11/21/19, 8:04 AM
Shares of Hepion Pharmaceuticals Inc. (HEPA) rocketed 57% in active trading to pace all premarket gainers, after the biopharmceutical company announced positive results from a preclinical study of its CRV431 liver cirrhosis treatment. Trading volume topped 836,000 shares, already more than half the full-day average of about 1.5 million shares. The company said late Wednesday that CRV431 prevented the development of liver cirrhosis in a "highly aggressive" model of liver disease. "The results align with previous findings in other experimental models and highlight the tremendous potential of CRV431 as a treatment for liver diseases, including NASH, where progression to cirrhosis is a primary medical concern," said Chief Executive Robert Foster. The stock had plunged 88% year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF (IBB) had climbed 18% and the S&P 500 had advanced 24%.
-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
11-21-19 0804ET
Copyright (c) 2019 Dow Jones & Company, Inc.
Nice!
Out at $4.70
Strike over! UAW Workers Ratify Contract with GM via Detroit Free Press
“GM is in talks to sell the facility to an investor group, Lordstown Motors, backed by electric truck maker Workhorse, plans to create 400 manufacturing jobs initially.
The potential of Lordstown Motors buying the plant and GM building a battery cell maker are options given, “they’re saying they want their workers to be UAW,” said O’Hara. But those are 18 to 24 months down the road, “so we can’t sustain ourselves financially that long. So I don’t know what that means for Local 1112.”
https://www.google.com/amp/s/amp.freep.com/amp/4057059002
I’ve been wondering the same thing. IPO seems logical.
10% interest in Lordstown Motors